Generex Biotechnology Revenue Growth Rates (GNBT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Generex Biotechnology Corp  (GNBT)
 

GNBT's Revenue Growth by Quarter and Year

Generex Biotechnology's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNBT Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter July -
3rd Quarter April 0.02
2nd Quarter January 0.00
1st Quarter October 0.09
FY 0.11





GNBT Revenue third quarter 2021 Y/Y Growth Comment
Generex Biotechnology Corp reported drop in Revenue in the third quarter 2021 by -95.86% to $ 0.02 millions, from the same quarter in 2020.
The fall in the third quarter 2021 Generex Biotechnology Corp's Revenue compares unfavorably to the Company's average Revenue doubling of 19348.04%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 237 other companies have achieved higher Revenue growth. While Generex Biotechnology Corp' s Revenue meltdown of -95.86% ranks overall at the positon no. 3777 in the third quarter 2021.


GNBT Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter July - - - -
3rd Quarter April -95.86 % -54.13 % - -
2nd Quarter January - -75 % 391.43 % -
1st Quarter October -87.5 % -79.07 % - -
FY   - -37.5 % 1031.43 % -

Financial Statements
Generex Biotechnology's third quarter 2021 Revenue $ 0.02 millions GNBT's Income Statement
Generex Biotechnology's third quarter 2020 Revenue $ 0.50 millions Quarterly GNBT's Income Statement


GNBT Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter July - 474 % - -
3rd Quarter April - -41.86 % -68.31 % -
2nd Quarter January - 19.44 % 0 % -
1st Quarter October -96.86 % - - -
FY (Year on Year)   - -37.5 % 1031.43 % -


Back to GNBT Growth rate Comparisons >> Back to GNBT Growth rate Comparisons >>


Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #238
Healthcare Sector #573
Overall #3777

Revenue Y/Y Growth Statistics
High Average Low
154917.85 % 19348.04 % -100 %
(Oct 31 2018)   (Jan 31 2021)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #238
Healthcare Sector #573
Overall #3777
Revenue Y/Y Growth Statistics
High Average Low
154917.85 % 19348.04 % -100 %
(Oct 31 2018)   (Jan 31 2021)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Generex Biotechnology's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNBT's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNBT's III. Quarter Q/Q Revenue Comment


Generex Biotechnology's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Apr 30 2021)		 12 Months Ending
(Jan 31 2021)		 12 Months Ending
(Oct 31 2020)		 12 Months Ending
(Jul 31 2020)		 12 Months Ending
(Apr 30 2020)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 4.32 $ 4.95 $ 2.03
Y / Y Revenue Growth (TTM) - - -17.06 % -37.5 % -74.58 %
Year on Year Revenue Growth Overall Ranking # 3557 # 0 # 3086 # 3547 # 0
Seqeuential Revenue Change (TTM) - - -12.79 % 144.25 % -22.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 3617 # 0 # 60 # 15 # 1582


Cumulative Revenue growth Comment
Generex Biotechnology Corp realized trailing twelve months of $ 0 millions, in the Apr 30 2021, compare to Revenue of $ 2 millions a year ago.

In the Healthcare sector 491 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3557.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 201
Healthcare Sector # 492
Overall # 3557

Revenue TTM Y/Y Growth Statistics
High Average Low
-30.39 %
 -49.77 %
-69.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 201
Sector # 500
S&P 500 # 3617
Cumulative Revenue growth Comment
Generex Biotechnology Corp realized trailing twelve months of $ 0 millions, in the Apr 30 2021, compare to Revenue of $ 2 millions a year ago.

In the Healthcare sector 491 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3557.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 201
Healthcare Sector # 492
Overall # 3557

Revenue TTM Y/Y Growth Statistics
High Average Low
-30.39 %
-49.77 %
-69.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 201
Sector # 500
S&P 500 # 3617




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GNBT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Apr 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Apr 30 2021
Integer Holdings Corporation-11.56%$ -11.558 millions
Rafael Holdings Inc-19.12%$ -19.118 millions
Lakeland Industries Inc -25.21%$ -25.207 millions
Generex Biotechnology Corp-95.85%$ -95.850 millions


About Generex Biotechnology Revenue Growth Rates (GNBT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.